These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21712955)

  • 1. Efficient allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi.
    de Yñigo-Mojado L; Martín-Ruíz I; Sutherland JD
    PLoS One; 2011; 6(6):e21352. PubMed ID: 21712955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of allele-specific RNAi effectors targeting genetic forms of Parkinson's disease.
    Sibley CR; Wood MJ
    PLoS One; 2011; 6(10):e26194. PubMed ID: 22031823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi.
    Ohnishi Y; Tamura Y; Yoshida M; Tokunaga K; Hohjoh H
    PLoS One; 2008 May; 3(5):e2248. PubMed ID: 18493311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic analysis of LRRK2 mutations in patients with Parkinson disease.
    Deng H; Le W; Guo Y; Hunter CB; Xie W; Huang M; Jankovic J
    J Neurol Sci; 2006 Dec; 251(1-2):102-6. PubMed ID: 17097110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.
    Gaig C; Ezquerra M; Marti MJ; Muñoz E; Valldeoriola F; Tolosa E
    Arch Neurol; 2006 Mar; 63(3):377-82. PubMed ID: 16533964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical features of LRRK2-associated Parkinson's disease].
    Pchelina SN; Ivanova ON; Emel'ianov AK; Iakimovskiĭ AF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12):56-62. PubMed ID: 22433811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redox proteomics analyses of the influence of co-expression of wild-type or mutated LRRK2 and Tau on C. elegans protein expression and oxidative modification: relevance to Parkinson disease.
    Di Domenico F; Sultana R; Ferree A; Smith K; Barone E; Perluigi M; Coccia R; Pierce W; Cai J; Mancuso C; Squillace R; Wiengele M; Dalle-Donne I; Wolozin B; Butterfield DA
    Antioxid Redox Signal; 2012 Dec; 17(11):1490-506. PubMed ID: 22315971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRRK2 mutations are a common cause of Parkinson's disease in Spain.
    Mata IF; Ross OA; Kachergus J; Huerta C; Ribacoba R; Moris G; Blazquez M; Guisasola LM; Salvador C; Martinez C; Farrer M; Alvarez V
    Eur J Neurol; 2006 Apr; 13(4):391-4. PubMed ID: 16643318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic screening for the LRRK2 R1441C and G2019S mutations in Parkinsonian patients from Campania.
    De Rosa A; De Michele G; Guacci A; Carbone R; Lieto M; Peluso S; Picillo M; Barone P; Salemi F; Laiso A; Saccà F; Tessitore A; Pellecchia MT; Bonifati V; Criscuolo C
    J Parkinsons Dis; 2014; 4(1):123-8. PubMed ID: 24496098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player.
    Häbig K; Walter M; Poths S; Riess O; Bonin M
    Neurogenetics; 2008 May; 9(2):83-94. PubMed ID: 18097693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2.
    Ruiz-Martínez J; de la Riva P; Rodríguez-Oroz MC; Mondragón Rezola E; Bergareche A; Gorostidi A; Gago B; Estanga A; Larrañaga N; Sarasqueta C; López de Munain A; Martí Massó JF
    Mov Disord; 2014 May; 29(6):750-5. PubMed ID: 24357540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain.
    Mata IF; Hutter CM; González-Fernández MC; de Pancorbo MM; Lezcano E; Huerta C; Blazquez M; Ribacoba R; Guisasola LM; Salvador C; Gómez-Esteban JC; Zarranz JJ; Infante J; Jankovic J; Deng H; Edwards KL; Alvarez V; Zabetian CP
    Neurogenetics; 2009 Oct; 10(4):347-53. PubMed ID: 19308469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Genetic screening for the LRRK2, G2019S and R1441 codon mutations in Parkinson's disease patients from Extremadura, Spain].
    Morán JM; Castellanos-Pinedo F; Casado-Naranjo I; Durán-Herrera C; Ramírez-Moreno JM; Gómez M; Zurdo-Hernández JM; Fuentes E; Ortiz-Ortiz MA; Moreno AD; González-Polo RA; Niso-Santano M; Bravo-Sanpedro JM; Pérez-Tur J; Ruiz-Mesa LM; Fuentes JM
    Rev Neurol; 2010 May; 50(10):591-4. PubMed ID: 20473834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology.
    Fujimoto T; Kuwahara T; Eguchi T; Sakurai M; Komori T; Iwatsubo T
    Biochem Biophys Res Commun; 2018 Jan; 495(2):1708-1715. PubMed ID: 29223392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.
    Floris G; Cannas A; Solla P; Murru MR; Tranquilli S; Corongiu D; Rolesu M; Cuccu S; Sardu C; Marrosu F; Marrosu MG
    Parkinsonism Relat Disord; 2009 May; 15(4):277-80. PubMed ID: 18805725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations.
    Ruiz-Martínez J; Gorostidi A; Goyenechea E; Alzualde A; Poza JJ; Rodríguez F; Bergareche A; Moreno F; López de Munain A; Martí Massó JF
    Mov Disord; 2011 Sep; 26(11):2026-31. PubMed ID: 21611983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.
    Gandhi PN; Chen SG; Wilson-Delfosse AL
    J Neurosci Res; 2009 May; 87(6):1283-95. PubMed ID: 19025767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.
    Somme JH; Molano Salazar A; Gonzalez A; Tijero B; Berganzo K; Lezcano E; Fernandez Martinez M; Zarranz JJ; Gómez-Esteban JC
    Parkinsonism Relat Disord; 2015 May; 21(5):494-9. PubMed ID: 25840672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model.
    Alegre-Abarrategui J; Christian H; Lufino MM; Mutihac R; Venda LL; Ansorge O; Wade-Martins R
    Hum Mol Genet; 2009 Nov; 18(21):4022-34. PubMed ID: 19640926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.